Ionis Pharmaceuticals's book value per share for the quarter that ended in Mar. 2026 was MXN53.41.
During the past 12 months, Ionis Pharmaceuticals's average Book Value Per Share Growth Rate was -1.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -9.40% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -11.80% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 7.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Ionis Pharmaceuticals was 526.60% per year. The lowest was -75.70% per year. And the median was -2.50% per year.
During the past 13 years, the highest P/B Ratio of Ionis Pharmaceuticals was 66.79. The lowest was 4.16. And the median was 10.46.
Ionis Pharmaceuticals (MEX:IONS) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Ionis Pharmaceuticals Book Value per Share Related Terms
Ionis Pharmaceuticals Book Value per Share Historical Data
* Premium members only.
The historical data trend for Ionis Pharmaceuticals's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:IONS vs EXEL, BBIO, AXSM: Book Value per Share Comparison
For the Biotechnology subindustry, Ionis Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ionis Pharmaceuticals PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ionis Pharmaceuticals's PB Ratio distribution charts can be found below:
* The bar in red indicates where Ionis Pharmaceuticals's PB Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Book Value per Share of MXN53.41 mean?
Ionis Pharmaceuticals (MEX:IONS) has a Book Value per Share of MXN53.41 as of Mar. 2026. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Ionis Pharmaceuticals and its competitors.
Is Ionis Pharmaceuticals' Book Value per Share too high?
Ionis Pharmaceuticals' current Book Value per Share is MXN53.41. Overall, Ionis Pharmaceuticals has a GF Score™ of 72/100, reflecting its overall financial health beyond just this single metric.
How does Ionis Pharmaceuticals' Book Value per Share compare to EXEL and BBIO?
Ionis Pharmaceuticals' Book Value per Share of MXN53.41 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Book Value per Share for a Biotechnology company?
A good Book Value per Share depends on the Biotechnology industry context. However, Book Value per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Book Value per Share mean?
A high Book Value per Share can signal that a stock is expensive relative to its fundamentals. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Ionis Pharmaceuticals and its competitors. Ionis Pharmaceuticals's current Book Value per Share is MXN53.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ionis Pharmaceuticals stock overvalued right now?
Ionis Pharmaceuticals (MEX:IONS) has a current Book Value per Share of MXN53.41. The stock's GF Value™ is MXN1,062.74, compared to a current price of MXN1,150.00 — trading 8.2% above its estimated fair value. The current Book Value per Share is MXN53.41. Ionis Pharmaceuticals' overall GF Score™ is 72/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Book Value per Share calculated?
Book Value per Share is calculated from a company's financial statements. For Ionis Pharmaceuticals (MEX:IONS), the current Book Value per Share is MXN53.41 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ionis Pharmaceuticals (MEX:IONS) Overvalued in 2026?
Based on GuruFocus' analysis, Ionis Pharmaceuticals stock appears to be overvalued.
The current stock price of MXN1,150.00 is trading 8.2% above its estimated GF Value™ of MXN1,062.74.
Key valuation signals for MEX:IONS:
Book Value per Share: MXN53.41
GF Value™: MXN1,062.74 vs. price of MXN1,150.00 (8.2% above fair value)
No single metric tells the full story. See the MEX:IONS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
72GF Score
Get the complete analysis for MEX:IONS
Book Value per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:IONS has been successfully added to your 
